GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the ...

GSK's stock price has significantly outperformed the healthcare sector this year, supported by its healthy Q1 2025 numbers. Both turnover and EPS growth exceeded expectations, and the company's ...

GSK (GSK) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.09 per share a year ago. These figures are ...

GSK has been found guilty of bringing discredit on the pharma industry after a complainant flagged “a shocking error” in the prescribing information for the JAK inhibitor Omjjara. A person who ...

GSK Plc reported better-than-expected profit in the first quarter as sales from its asthma and HIV drugs offset a lackluster vaccine performance. The UK drugmaker’s shares surged after it ...

As GSK weathers the storm of sinking vaccine sales and gears up for key launches in its specialty medicines sector, the British drug giant feels prepared for any challenges that U.S. drug import ...

Royalty Income for 2025: Expected to be GBP 750 to 800 million. GSK PLC (NYSE:GSK) reported a 4% increase in group sales and a 5% rise in operating profit, demonstrating the strength and ...

GSK’s profit rose on better-than-expected performance of HIV, cancer and asthma treatments, offsetting lower vaccine demand in the U.S. GSK plans to bring five new specialty medicines to market ...

Drugmaker GSK (GSK.L) (GlaxoSmithKline) has said it is “well positioned” to cope with any financial impact from changes to US tariff rules. It came as the FTSE 100 (^FTSE) giant revealed a rise in ...

Learn More. While the company’s long-term performance has lagged behind key rival AstraZeneca, recent momentum has ignited a degree of optimism that GSK may finally be turning a corner after ...